MedPath
Found 452 clinical trials|View Analysis
Sort by:
Need a comprehensive medical report on "RNA"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals

Evaluation of the Use of the GenXpert to Detect Hepatitis C RNA

Not Applicable
Conditions
Drug Use
Hepatitis C
First Posted Date
2021-01-22
Last Posted Date
2021-01-22
Lead Sponsor
Hasselt University
Target Recruit Count
300
Registration Number
NCT04717856
Locations
🇧🇪

Hasselt University, Diepenbeek, Belgium

A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

Phase 3
Completed
Conditions
SARS-CoV-2 Infection
COVID-19
Interventions
Biological: BNT162b2
Biological: BNT162b2.B.1.351
First Posted Date
2021-01-19
Last Posted Date
2022-12-22
Lead Sponsor
BioNTech SE
Target Recruit Count
1574
Registration Number
NCT04713553
Locations
🇺🇸

Clinical Research Consulting, Milford, Connecticut, United States

🇺🇸

Clinical Research Atlanta, Stockbridge, Georgia, United States

🇺🇸

Amici Clinical Research LLC, Raritan, New Jersey, United States

and more 13 locations

The Role of m6A RNA Modification in Moyamoya Disease

Conditions
Moyamoya Disease
First Posted Date
2021-01-06
Last Posted Date
2022-02-17
Lead Sponsor
Beijing Tiantan Hospital
Target Recruit Count
160
Registration Number
NCT04696094
Locations
🇨🇳

Beijing Tiantan Hospital Capital Medical University, Beijing, Beijing, China

Novelty, Conformity and Trust in COVID-19 Vaccines

Not Applicable
Completed
Conditions
Trust
Interventions
Other: Conventional vaccine
Other: 40% adoption rate
Other: 60% adoption rate
Other: 20% adoption rate
Other: RNA vaccine
Other: 0% adoption rate
Other: 80% adoption rate
First Posted Date
2021-01-05
Last Posted Date
2022-02-22
Lead Sponsor
National University of Singapore
Target Recruit Count
35180
Registration Number
NCT04693689
Locations
🇺🇸

SurveyMonkey, San Mateo, California, United States

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Phase 2
Recruiting
Conditions
Pancreatic Cancer
Interventions
Drug: Gemcitabine/Nab-paclitaxel Treatment Regimen
Drug: mFOLFIRINOX Treatment Regimen
Radiation: Chemoradiation
First Posted Date
2020-12-24
Last Posted Date
2024-11-21
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
87
Registration Number
NCT04683315
Locations
🇺🇸

HonorHealth Medical Group, Scottsdale, Arizona, United States

🇺🇸

Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing

Conditions
Prurigo Nodularis
Atopic Dermatitis
Interventions
Other: Plastic surgery remnants
Other: Skin biopsy
First Posted Date
2020-12-23
Last Posted Date
2021-02-09
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
20
Registration Number
NCT04681300

Host RNA Signature in Children With Cancer and Infection

Completed
Conditions
Infection
Childhood Cancer
Neutropenia, Febrile
Interventions
Diagnostic Test: RNA expression signature
First Posted Date
2020-12-16
Last Posted Date
2022-12-22
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
370
Registration Number
NCT04669418
Locations
🇩🇰

Department of Pediatrics, Aalborg University Hospital, Aalborg, Denmark

🇩🇰

Center for Genomic Medicine, Copenhagen, Denmark

🇩🇰

Department of Pediatric Oncology, Aarhus University Hospital, Aarhus, Denmark

and more 2 locations

A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

Phase 2
Terminated
Conditions
SARS-CoV Infection
Corona Virus Infection
Covid19
Interventions
Biological: ARCT-021 two lower dose priming
Biological: ARCT-021 single dose priming
Biological: ARCT-021 two higher dose priming
Biological: Placebo (two doses), priming
Biological: Randomized booster
Biological: Placebo booster
First Posted Date
2020-12-16
Last Posted Date
2025-05-15
Lead Sponsor
Arcturus Therapeutics, Inc.
Target Recruit Count
581
Registration Number
NCT04668339
Locations
🇸🇬

Arcturus Investigational Site 201, Singapore, Singapore

🇺🇸

Arcturus Investigational Site 107, Tucson, Arizona, United States

🇺🇸

Arcturus Investigational Site 112, San Diego, California, United States

and more 12 locations

Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)

Terminated
Conditions
Influenza
RNA Virus Infections
Infection, Bacterial
Infection Viral
Respiratory Viral Infection
Respiratory Tract Infections
Covid19
SARS (Severe Acute Respiratory Syndrome)
First Posted Date
2020-12-11
Last Posted Date
2024-05-17
Lead Sponsor
Imperial College London
Target Recruit Count
8
Registration Number
NCT04664075
Locations
🇬🇧

Imperial College London, London, United Kingdom

A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety

Phase 3
Completed
Conditions
Rhabdoviridae Infections
RNA Virus Infections
Rabies
Communicable Disease
Virus Diseases
Mononegavirales Infections
Interventions
Biological: Human Rabies Immune Globulin (HRIG)
Biological: SYN023
Biological: Rabies Vaccine
First Posted Date
2020-11-25
Last Posted Date
2023-04-21
Lead Sponsor
Synermore Biologics (Suzhou) Co., Ltd.
Target Recruit Count
1000
Registration Number
NCT04644484
Locations
🇨🇳

Yunnan Province Center for Disease Control and Prevention (CDC), Kunming, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy